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 › Some diseases are particularly raging in poor countries 
leading to a considerable burden of diseases in these 
countries. Besides insufficient local medical care, the 
innovation system of industrialised countries is held 
responsible for this problem.
 › The diseases are considered to be neglected, because in-
dustry has little incentive to develop new medicines and 
medical devices due to the financially weak demand. In 
recent years, national and international measures have 
been discussed and partly been implemented in order 
to deliberately strengthen research and development 
(R&D) with regard to such diseases and to make new 
medicines affordable for poor countries as well.
 › Germany is one of the world‘s leading locations for me-
dical R&D. Yet with regard to fighting neglected diseases, 
Germany lags behind compared to several other indus-
trialised countries. The TAB report gives an overview of 
various measures aiming at strengthening research and 
product development to fight against neglected diseases 
and identifies options for a stronger political commit-
ment in Germany.
sation. In the industrialised countries, the manufacturers of 
new medicines are responsible for these complex R&D acti-
vities and bear the costs. In return, they are granted intellec-
tual property rights ensuring them the temporary exclusive 
commercial use of their developments and promising them 
positive R&D investment returns via monopoly prices. Thus, 
in the industrialised countries, it has been possible to com-
mercialise considerable R&D activities. Public budgets are 
not burdened by the costs of product development, but by 
high product prices caused by the monopoly. International 
treaties increasingly secure the enforceability of these intel-
lectual property rights worldwide. On the one hand, one of 
the effects of these structures is that new medicines are very 
expensive over several years – and thus mostly unaffordable 
for poor countries (access issue). On the other hand, there is 
a lack of sufficient product development regarding diseases 
almost exclusively affecting poor countries (R&D issue). In 
this case, another challenge has to be faced: The complex 
clinical trials to prove the efficacy of new medicines have 
to be carried out in mostly large patient populations as well 
as in the affected regions. For this, both clinical centers for 
carrying out the trials and governance structures for approv- 
ing and monitoring the R&D activities are required which 
still need to be built up or at least further developed in poor 
countries.
As the established commercialised R&D structures of the 
pharmacological innovation system are at least not fully 
functional in case of a low and/or financially weak demand, 
additional measures are to be taken in order to provide an 
incentive for the necessary research and product develop-
ment.
What is involved
Poverty-related and neglected diseases (PRND) are disea-
ses mainly occurring in poor countries for which industry 
hardly develops any new products. Mostly, the so-called 
»big three« (tuberculosis, malaria, HIV/AIDS), most of the 
17 neglected tropical diseases defined by the WHO as well 
as some respiratory and diarrhoeal diseases are referred to 
as poverty-related and neglected – all of them being infec-
tious diseases.
Before new medicines are authorised to be used in industri- 
alised countries, it is necessary to prove their safety, efficacy 
and quality. This has to be ensured by means of a structured 
procedure with several R&D phases. Clinical trials – first in 
healthy volunteers and then, step by step, in larger patient 
populations – are the core piece relevant for market authori-
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2000
300 test persons, 3 vaccinations; 
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the phase III trial
2014
Application for marketing authorisation
1984
Development of the genetically recombined
vaccine candidate RTS,S
Walter Reed Army Institute of Reseach (USA)         R&D expenditures: not quantified                  Exit
R&D costs: 600 million US-Dollar
R&D costs: not quantifiedVarious scientific cooperation projects
Involvement of the non-profit PDP »MVI PATH« R&D costs: 200 million US-Dollar
R&D involvement of SmithKline Beecham (Belgium, merger to form GlaxoSmithKline in 2002)
its administrative, organisational and financial limits. Parti- 
cularly activities with regard to clinical trials to prove effi- 
cacy are financed on a joint basis. So far, public institutions 
are participating in the partnership almost exclusively. Since 
it was established in 2003, the EDCTP carried out many 
training activities, published numerous research results and 
further developed several product candidates, though none 
of them received market authorisation so far.
Product development partnerships (PDP): Since the turn 
of the millennium, numerous non-profit organisations with 
their own financing (donations, public funding) have emerg- 
ed, which at least partly take over R&D tasks in case of fail- 
ing market mechanisms. With regard to PRND activities, 
they have become a link between public institutions and in-
dustry. In cooperation with industry, first application exten-
sions of already available active pharmaceutical ingredients 
could be approved. Since the financial crisis, however, the 
available funds are decreasing. Currently, it is open whether 
PDPs will be able to provide the necessary resources in order 
to attain marketing authorisation for completely new active 
pharmaceutical ingredients, because in later clinical R&D 
phases there is an increase of expenditures and thus of the 
financial requirements involved.
Additional sources of R&D funding: In recent years, there 
have been discussions on whether and how new and/or ad-
ditional sources of funding for R&D regarding PRND can be 
tapped. In 2006, some industrialised and newly industrial- 
ised countries launched an initiative to generate additional 
funds by means of solidarity levies on airline tickets. How- 
ever, there is neither an implementation of these levies nor 
of any other surcharges (e. g. for financial transactions) on a 
global scale. So far, even ideas of setting up additional funds 
to finance R&D have been hardly accepted to a relevant ex-
tent. Though expert panels of the WHO have been calling 
for measures ranging from a global research convention to 
Elements for strengthening R&D
Evidence-based medicine of industrialised countries requires 
various R&D activities which are assigned to different phases 
(from basic research and clinical trials to surveillance under 
conditions of use), but which are often entwined in terms of 
time and content (see case study in the figure below). Mea- 
sures aiming at improving the situation tackle different pha-
ses of this procedure.
Public research funding: In the industrialised countries, the-
re is a certain division of responsibilities between the public 
sector (funding of basic research) and industry (financing of 
product development). In recent years, many countries have 
enhanced their research funding capacities and thus have 
mainly strengthened basic research in their public institu-
tions. Typically, the available public funds of individual coun-
tries are not sufficient to secure the implementation of clini-
cal trials requiring authorisation in countries of the »Global 
South« as well as efficient product development so that other 
sources of funding (from pharmaceutical companies to phi-
lanthropic foundations) play an important role as well.
Open innovation: Some stakeholder are starting to open in-
dividual R&D instruments for PRND activities and to develop 
products together. Open innovation comprises the following: 
open access (access to publications), open data (access to 
R&D data) as well as the opening of R&D infrastructures for 
PRND activities (substance libraries, laboratory facilities) or 
approaches regarding the shared use of intellectual property 
rights for this purpose (patent pools). Beyond open access, 
opportunities for use for certain R&D actors and/or defined 
PRND activities currently are more likely to become realised 
than an absolutely free access.
European & Developing Countries Clinical Trials Part-
nership (EDCTP): The EDCTP is financed by the European 
Commission and several European countries on equal terms 
in order to increase capacities and know-how for organising 
and conducting clinical trials in Sub-Saharan Africa. The 
EDCTP comes into play where public R&D funding reaches 
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Situation in Germany
Germany as a location for R&D has highly-competent pub-
lic and private-sector institutions which in total cover almost 
the entire range of diseases and products. Particular strength 
with regard to fighting PRNDs can be found in tuberculosis 
research as well as in the development of diagnostic methods 
and insecticide-containing products for malaria prevention. 
Though it is difficult to give a detailed overview of the com-
mitment of the public sector with regard to funding R&D 
of PRND, international studies conclude that Germany lags 
behind several other industrialised countries with regard 
to the public funding of R&D for PRND. When it comes to 
strengthen R&D with regard to PRND, German stakeholder 
are not among the pioneers – neither regarding open inno- 
vation activities nor regarding funding instruments for busi- 
ness development.
According to the German Federal Government, in particu-
lar the German Federal Ministry of Education and Research 
(BMBF) is responsible for strengthening R&D for PRND. In 
2011 for the first time, the BMBF set up a PRND research 
funding concept which bundles major measures (public 
research funding, promotion of PDPs, participation in the 
EDCTP) and, since 2014, is also intended to boost sustain-
able health research cooperation between Germany and the 
countries of Sub-Saharan Africa, thus complying with the 
Ministry’s »Africa Strategy«. This was accompanied by re- 
structuring national activities (networking between exist- 
ing public research institutions within the framework of the 
German Center for Infection Research) and a reassignment 
of departmental responsibilities (originally, the Federal 
Ministry for Economic Cooperation and Development 
[BMZ] was responsible for PDP funding) which first made 
it necessary again to bundle resources and to gather experi-
ence. Also with regard to a financial reinforcement of some 
funding measures since 2014, Germany falls behind other 
industrialized countries. It seems to be almost impossible 
that the intended amounts are sufficient to rapidly push 
product development.
obligatory contributions to R&D regarding PRND for several 
years now, the suggested forms of those measures have not 
been supported very much by the member states so far.
R&D incentives for businesses: Some industrialised coun-
tries try to offer targeted incentives for private-sector com-
mitment, i. a. with tax credits for specific R&D, performan-
ce-based rewards via vouchers for fast-track authorisation 
procedures or by massively strengthening and ensuring the 
product demand. There are different opinions whether such 
measures can stimulate economic commitment to PRND 
product development to a significant extent.
Assistance for product authorisation: European and US 
drug regulatory authorities have established procedures in 
order to ensure a fast and cost-effective assessment of the 
benefits and risks of new medicines to fight against PRND. 
Procedures by the WHO help with the quality assessment of 
medicines and medical devices against PRND (centralised 
product prequalification). These are major elements to be 
able to provide socially acceptable access to new products 
via global initiatives.
Equitable access to products: Some bilateral and multilate-
ral initiatives are aiming at providing medicines and medi-
cal products particularly in the least developed countries as 
extensively and cost-effectively as possible. So far, however, 
they only cover some areas of the global market. The »GAVI 
Alliance« pools the demand for vaccines of approx. 50 de-
veloping countries and subsidises the vaccines up to a free 
provision for the 20 poorest countries. The »Global Fund« 
supports approx. 100 countries in getting access to medicines 
and medical devices, but only to fight the »big three«. On the 
one hand, these initiatives are aiming at massively supporting 
mainly the poorest countries, but also at increasingly involv- 
ing countries with a higher economic potential in the costs. 
On the other hand, bundling and boosting the demand shall 
strengthen market mechanisms.
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Options for action
The funding concept by the BMBF is a major step to reduce 
the neglect of poverty-related diseases with regard to R&D. 
It can help to develop, approve and provide products to fight 
these diseases. The impact of the funding concept can be 
increased by adding other research policy elements and 
interlinking them with activities regarding economic, 
development and health policy.
For this purpose, the established research infrastructures 
should be opened up for PRND activities (keyword: open 
innovation) and used more frequently (e. g. PRND-specific 
areas regarding the process, access and application as well as 
contact persons). Furthermore, the documentation of natio- 
nal commitment regarding R&D for PRND shall play a 
more important role in the future.
A significant part of the necessary R&D activities can only be 
carried out in countries where the respective diseases are en-
demic. For this reason, the required local clinical centers and 
supervisory institutions have to be strengthened. As, besides 
their research tasks, these clinics also have responsibilities 
regarding medical care, measures of research funding and 
development cooperation should be interlinked. So far, 
some regulatory authorities of industrialised countries and 
the WHO are bridging the gaps of incomplete local govern- 
ance structures especially in Sub-Saharan Africa, are helping 
with approvals for trials and are particularly taking over tasks 
of benefit and quality assessment within the framework of 
product authorisation. Besides ensuring this bridging pro-
cess organisationally and financially, the necessary structures 
in the »Global South« should be further developed in order 
to reduce the associated dependency on the industrialised 
countries. To achieve this, the aim is to link scientific coope-
ration, technical development assistance and internatio- 
nal health policy efforts.
Some multilateral initiatives support equitable access to 
quality-controlled medicines and medical devices parti-
cularly for poor countries in individual areas of the global 
market. The health-related effects of these initiatives could be 
increased, if the currently highly fragmented coverage could 
be extended.
As, in the established innovation system, product develop-
ment is mostly carried out within the private sector and 
market authorisation is achieved there, some industrialised 
countries – in case of weak market mechanisms – try to offer 
incentives for private-sector commitment via economic po-
licy measures (tax credits for R&D measures, rewards for 
product development, R&D funds). In Germany, at least a 
debate on a targeted stimulation of private-sector commit-
ment regarding PRND should be initiated, given that the 
funding of public and non-profit R&D for PRND is still 
rather reluctant compared to other countries and that the 
chances of finding an international agreement regarding ade-
quate additional forms of financing are rather small. More- 
over, it should be verified whether and to what extent estab-
lished measures to support private-sector commitment (e. g. 
»Export Initiative for the German Health Care Industry«, 
»KMU-innovativ« [national initiative promoting innova- 
tion in Small and Medium Enterpreises]) are also focusing on 
poverty-related diseases.
Different department-specific measures to strengthen re- 
search, product development and product provision as well 
as medical supply regarding poverty-related diseases should 
be merged to an overall strategy of the German Federal 
Government and should be further developed. Regular pro-
gress reports should be agreed upon.
